Should Belatacept Be the Centrepiece of Renal Transplantation?

Monika Huber; Stephan Kemmner; Lutz Renders; Uwe Heemann


Nephrol Dial Transplant. 2016;31(12):1995-2002. 

In This Article


With the selective co-stimulation blocker belatacept, a less toxic, CNI-free immunosuppressive regimen has appeared as a real option for carefully selected patients. The first group consists of patients for whom the favourable cardiovascular risk profile and improved renal function is important; e.g. patients receiving ECD kidneys and patients with pre-existing cardiovascular diseases. The second group consists of patients with already diagnosed chronic allograft nephropathy, CNI toxicity, CNI-induced thrombotic microangiopathy or delayed graft function, to possibly preserve and prolong allograft survival. The third group consists of patients with non-compliance to oral immunosuppressive therapy, as this is a known risk factor for allograft failure.